Investor Watch | Biotech Hedge Fund Losses Mount but Enormous Sums of Capital Available

While many people just assume biotech investors make big returns during the pandemic, perhaps nothing could be farther from the truth for many investors in this traditionally high volatile market. Recently, the Wall Street Journal reported that “The performance of the biotech sector this year is worse than all 11 of the S&P 500’s sectors.” Biotech stock prices overall have fallen after 2019 and 2020 surges. While some biotech and pharma companies were “winners,” most have missed out on the opportunity to monetize the pandemic. Looming questions and issues mount—spooking potential investors—which, of course, can adversely impact share prices. Do some noticeable losses in hedge funds introduce more risk or opportunity?

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee